insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk preps for speedy oral GLP-1 drug filing

Group sales barely moved in 2018 compared to the prior year, coming in at 112bn krone, with the GLP-1 portfolio’s growth offsetting declines in insulin products. ... 10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a

Latest news

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation
Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Victoza’s performance meant that Novo Nordisk was able to weather the pressure in the insulins market, which kept its overall insulin sales flat at DKK 14.66bn. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

insulin degludec/liraglutide).
Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine. Novo Nordisk has filed new data to the FDA showing its long-acting insulin Tresiba is less likely to cause low blood sugar ... The Danish drugmaker wants the results of the DEVOTE trial -
Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo

More from news
Approximately 12 fully matching, plus 55 partially matching documents found.

Latest Intelligence

Interview: Peter Meeus, Novo Nordisk

Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Up to £50, 000 with Benefits

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Digital Account Director: Salary TBC

Senior Medical Writer: Great salary and benefits

Project Manager/ Account Manager: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Director, Medical Education: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Subscribe to our email news alerts

PMHub

Add my company

Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....